Boehringer Ingelheim GmbH is to enlist the help of a UK company specialising in artificial intelligence (AI) to identify new indications for rare neurological diseases. The partnership, with Healx Ltd of the UK, involves exploiting assets that are already in BI’s portfolio. The financial terms of the agreement weren’t disclosed.
